NO985231L - Forbindelser som fremmer vevsvekst - Google Patents

Forbindelser som fremmer vevsvekst

Info

Publication number
NO985231L
NO985231L NO985231A NO985231A NO985231L NO 985231 L NO985231 L NO 985231L NO 985231 A NO985231 A NO 985231A NO 985231 A NO985231 A NO 985231A NO 985231 L NO985231 L NO 985231L
Authority
NO
Norway
Prior art keywords
seq
human
cdna
retl
retl3
Prior art date
Application number
NO985231A
Other languages
English (en)
Other versions
NO985231D0 (no
NO323612B1 (no
Inventor
Michele Sanicola-Nadel
Catherine Hession
Richard L Cate
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO985231D0 publication Critical patent/NO985231D0/no
Publication of NO985231L publication Critical patent/NO985231L/no
Publication of NO323612B1 publication Critical patent/NO323612B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19985231A 1996-05-08 1998-11-09 Ret-ligandb3 (RetL3) for stimulering av neural og renal vekst, nukleinsyrer som koder for polypeptidet, fusjonsprotein samt antistoff som spesifikt binder polypeptidet. NO323612B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1742796P 1996-05-08 1996-05-08
US1930096P 1996-06-07 1996-06-07
US2185996P 1996-07-16 1996-07-16
US4353397P 1997-04-11 1997-04-11
PCT/US1997/007726 WO1997044356A2 (en) 1996-05-08 1997-05-07 RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH

Publications (3)

Publication Number Publication Date
NO985231D0 NO985231D0 (no) 1998-11-09
NO985231L true NO985231L (no) 1999-01-08
NO323612B1 NO323612B1 (no) 2007-06-18

Family

ID=27360789

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19985231A NO323612B1 (no) 1996-05-08 1998-11-09 Ret-ligandb3 (RetL3) for stimulering av neural og renal vekst, nukleinsyrer som koder for polypeptidet, fusjonsprotein samt antistoff som spesifikt binder polypeptidet.
NO20065528A NO324957B1 (no) 1996-05-08 2006-11-30 Anvendelse av monoklonalt antistoff for fremstilling av medikament til behandling av Ret-assosierte lidelser.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20065528A NO324957B1 (no) 1996-05-08 2006-11-30 Anvendelse av monoklonalt antistoff for fremstilling av medikament til behandling av Ret-assosierte lidelser.

Country Status (24)

Country Link
EP (2) EP1757617A1 (no)
JP (1) JP2002515743A (no)
KR (2) KR100587556B1 (no)
CN (2) CN1163509C (no)
AT (1) ATE335003T1 (no)
AU (1) AU732392B2 (no)
BG (2) BG109433A (no)
BR (1) BR9710665A (no)
CA (1) CA2253871C (no)
CZ (1) CZ296516B6 (no)
DE (1) DE69736428T2 (no)
DK (1) DK0914339T3 (no)
EA (1) EA002544B1 (no)
EE (1) EE9800377A (no)
ES (1) ES2270465T3 (no)
IL (1) IL126918A (no)
IS (1) IS2361B (no)
NO (2) NO323612B1 (no)
NZ (1) NZ332706A (no)
PT (1) PT914339E (no)
RO (1) RO120343B1 (no)
SK (1) SK286115B6 (no)
TR (2) TR200103297T2 (no)
WO (1) WO1997044356A2 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
EP0846764A3 (en) * 1996-11-27 1998-09-30 Smithkline Beecham Plc Glial cell line-derived neurotrophic factor alpha receptor family
WO1998024905A2 (en) * 1996-12-06 1998-06-11 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6372453B1 (en) 1997-02-18 2002-04-16 Genetech, Inc. Neurturin receptor
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
WO1998036072A1 (en) * 1997-02-18 1998-08-20 Genentech, Inc. Neurturin receptor
US6025157A (en) 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
NZ501423A (en) * 1997-04-17 2002-02-01 Univ Washington Receptors for TGF-beta-related neurotrophic factors and use for treating disease
WO1998053069A2 (en) * 1997-05-20 1998-11-26 Human Genome Sciences, Inc. Gdnf receptors
NZ501199A (en) * 1997-05-22 2001-12-21 Carlos F Glial cell line-derived neurotrophic factor receptors (BDNFR-beta)
JP2002505576A (ja) * 1997-05-30 2002-02-19 アムジエン・インコーポレーテツド 神経栄養因子レセプター
AU765070B2 (en) * 1998-03-23 2003-09-11 Genentech Inc. GFRalpha3 and its uses
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2001016169A2 (en) * 1999-09-01 2001-03-08 Biogen, Inc. RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE
ES2351215T3 (es) 2003-01-31 2011-02-01 Biogen Idec Ma Inc. Conjugados poliméricos de neublastina mutada.
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
US10023855B2 (en) * 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
WO2014017491A1 (ja) * 2012-07-26 2014-01-30 独立行政法人国立がん研究センター Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
WO2014176696A1 (en) 2013-04-30 2014-11-06 Université de Montréal Novel biomarkers for acute myeloid leukemia
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5185154A (en) 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP3021800B2 (ja) 1990-07-24 2000-03-15 セイコーエプソン株式会社 半導体装置及びその製造方法
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
FR2693107B1 (fr) 1992-07-01 1994-09-23 Chauvin Laboratoire Moyens pour la prévention de la cataracte secondaire.
AU1404395A (en) * 1993-12-13 1995-07-03 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
NZ324511A (en) * 1995-11-13 1999-09-29 Carlos Ibanez Identification and isolation of glial cell line-derived neurotrophic factor receptors (gdnf receptors)
JP4301347B2 (ja) * 1996-03-14 2009-07-22 ジェネンテク， インコーポレイテッド Ｇｄｎｆおよびｇｄｎｆ受容体の用途
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides

Also Published As

Publication number Publication date
CA2253871C (en) 2005-04-26
AU3472997A (en) 1997-12-09
NO985231D0 (no) 1998-11-09
CZ361598A3 (cs) 1999-03-17
IL126918A0 (en) 1999-09-22
NZ332706A (en) 1999-10-28
CN1163509C (zh) 2004-08-25
IS4884A (is) 1998-11-06
EA002544B1 (ru) 2002-06-27
DE69736428D1 (de) 2006-09-14
CA2253871A1 (en) 1997-11-27
IL126918A (en) 2007-06-03
ATE335003T1 (de) 2006-08-15
BG109433A (en) 2007-08-31
EP0914339B1 (en) 2006-08-02
PT914339E (pt) 2006-12-29
NO20065528L (no) 1999-01-08
EP0914339A2 (en) 1999-05-12
EE9800377A (et) 1999-04-15
JP2002515743A (ja) 2002-05-28
AU732392B2 (en) 2001-04-26
CN1624126A (zh) 2005-06-08
KR20050056275A (ko) 2005-06-14
CZ296516B6 (cs) 2006-04-12
WO1997044356A3 (en) 1998-02-19
SK286115B6 (sk) 2008-03-05
RO120343B1 (ro) 2005-12-30
SK152498A3 (en) 1999-08-06
TR199802252T2 (xx) 1999-02-22
BG102973A (en) 1999-08-31
DK0914339T3 (da) 2006-12-04
EP1757617A1 (en) 2007-02-28
DE69736428T2 (de) 2007-08-30
BG64907B1 (bg) 2006-08-31
EA199800990A1 (ru) 1999-06-24
NO324957B1 (no) 2008-01-14
IS2361B (is) 2008-05-15
KR20060024843A (ko) 2006-03-17
ES2270465T3 (es) 2007-04-01
CN1232469A (zh) 1999-10-20
BR9710665A (pt) 1999-08-17
NO323612B1 (no) 2007-06-18
WO1997044356A2 (en) 1997-11-27
TR200103297T2 (tr) 2002-06-21
KR100587556B1 (ko) 2006-06-08

Similar Documents

Publication Publication Date Title
NO20065528L (no) Forbindelser som fremmer vevsvekst.
DE69737740D1 (de) GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
KR970700438A (ko) 마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g))
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
DK0955313T3 (da) Nyt protein og fremgangsmåde til fremstilling af samme
ATE430197T1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
WO1995021919A3 (en) Protein having tpo activity
PT917571E (pt) Gene relacionado com agouti
ATE346083T1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
EE200100472A (et) Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks
KR920004571A (ko) 헤파린 결합 향신경성 인자(hbnf)를 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, 및 hbnf의 생성 방법 및 사용방법
ATE321856T1 (de) Humane rezeptortyrosinkinase
ATE192490T1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
WO1998011234A3 (en) Human protein kinases
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
DE3854420D1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
MX9504057A (es) Proteina que tiene actividad tpo.
WO2005047316A3 (en) Insulin releasing peptides